Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report.

Patients with erythrodermic psoriasis (EP) complicated by end-stage renal disease (ESRD) requiring hemodialysis are extremely rare in clinical practice, and treatment options for this specific population remain highly limited. Herein we report a case of an EP patient with ESRD, in whom treatment with an interleukin-17 (IL-17) inhibitor secukinumab not only rapidly alleviated erythrodermic symptoms but also resulted in a certain degree of improvement in renal function. At the 7-month follow-up, the patient maintained skin lesion clearance with no deterioration in renal function-a finding that has not been consistently documented in previous literature. This case suggests that for patients with psoriasis complicated by kidney disease IL-17 inhibitors may serve as a potentially favorable therapeutic option.